Expert Interview
A Second Opinion: Looking at the potential of Monte Rosa's Molecular Glue Degrader, MRT-2359, for the treatment of Prostate Cancer
Ticker(s): GLUE, ALPMF, PFE, JNJ, AMGN, NVSInstitution: University of Minnesota (formerly Hopkins)
- Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
- Clinical interest is the management of prostate cancer and other genitourinary malignancies.
- Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches.
Roughly how many patients do you treat with prostate cancer
If you had to rate your level of excitement on a 1 to 10 scale for the potential of MRT-2359, what would it be and why?
Added By: ben_adminWhat is your opinion the response rate and safety profile of MRT-2359?
Added By: ben_adminWhere would MRT-2359 fit into your treatment algorithm of prostate cancer if it was approved?
Added By: ben_adminPlease describe your background and practice setting
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
